Nikkarinen Anna, Glimelius Ingrid
Department of Immunology Genetics and Pathology, Cancer Precision Medicine Uppsala University Uppsala Sweden.
EJHaem. 2024 Jun 16;5(4):820-824. doi: 10.1002/jha2.929. eCollection 2024 Aug.
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable. However, here we present two cases of life-threatening aplastic anemia (AA) upon treatment with the BTKi acalabrutinib for MCL. The first patient died of neutropenic infection secondary to AA. The second patient was successfully treated with immunosuppressive treatment but the MCL relapsed shortly thereafter. AA is a potentially fatal complication that should be considered when patients present with pancytopenia during treatment with BTKi.
布鲁顿酪氨酸激酶抑制剂（BTKi）在套细胞淋巴瘤（MCL）患者中的使用正在迅速增加。迄今为止报告的副作用通常是可控的。然而，我们在此报告两例使用BTKi阿卡替尼治疗MCL时发生危及生命的再生障碍性贫血（AA）的病例。首例患者死于继发于AA的中性粒细胞减少感染。第二例患者接受免疫抑制治疗后成功治愈，但此后不久MCL复发。AA是一种潜在的致命并发症，当患者在使用BTKi治疗期间出现全血细胞减少时应予以考虑。
